Drugs belonging to class 'Epidermal growth factor receptor (EGFR) inhibitor / antagonist'
See adverse reactions attributed to class 'Epidermal growth factor receptor (EGFR) inhibitor / antagonist'
| Drug Name | Compare |
|---|---|
| Afatinib |  |
| Cetuximab | |
| Dacomitinib | |
| Erlotinib | |
| Gefitinib | |
| Lapatinib | |
| Mobocertinib | |
| Necitumumab | |
| Neratinib | |
| Osimertinib | |
| Panitumumab | |
| Vandetanib | |
Adverse reactions attributed to entire drug class 'Epidermal growth factor receptor (EGFR) inhibitor / antagonist'
Please login to view adverse reactions
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
